2023 Annual Symposium For Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond

Herndon, VA US
September 29, 2023 to September 30, 2023

This CME-accredited activity, “2023 Annual Symposium for Evolving Therapies and Drug Development in Oncology: Targeted therapy, immunotherapy and beyond”, is a two-day conference aimed at improving the knowledge and competence of academic and community oncology providers on the biomarker-guided treatment of cancer, and design and conduct of clinical trials in the era of novel therapies. The activity will use a mix of didactic lectures and panel discussions to highlight various aspects of precision oncology, including current challenges and opportunities in designing clinical trials in the era of novel therapies.

Target Audience

  • Hematology/Oncology physicians
  • NPs/PAs
  • Residents/fellows
  • Pharmacists
  • Nurses

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review recent updates in biomarker-guided treatment options for cancer patients.
  • Review challenges and trends in drug development in the era of novel therapies.
  • Outline the best practices for the conduct of Phase I clinical trials in the era of novel therapies.
  • Identify the phase I clinical trials to match patients’ needs.
  • Review the challenges and potential solutions for the diverse representation during drug development.

 

BRONZE SPONSOR

image

 

Course summary
Available credit: 
  • 8.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.00 Contact Hours.
Course opens: 
05/01/2023
Course expires: 
11/30/2023
Event starts: 
09/29/2023 - 3:00pm PDT
Event ends: 
09/30/2023 - 5:00pm PDT
Cost:
$100.00
Add to calendar: 

Conference Chairs: Nagla Abdel Karim, MD, PhD and Vivek Subbiah, MD

Honorary President: Alex Spira, MD, PhD, FACP

Day 1 - September 29, 2023

All times below are listed in Eastern Standard Time (EST).

03:00 PM - 04:00 PM - REGISTRATION & NETWORKING

04:00 PM - 04:05 PM - Welcome Note - Nagla Karim, MD

04:05 PM - 04:15 PM - Welcome Remarks - Binay Shah, MD

04:15 PM - 05:15 PM - SESSION 1: EVOLVING TARGETED THERAPIES                                                                                                   

Session Chair: Raymond Wadlow, MD

04:15 PM - 04:30 PM - Tumor Agnostic Drug Development - Vivek Subbiah, MD

04:30 PM - 04:45 PM - Quality of Life as Measurement of Success for Clinical Trial Ishwaria Subbiah, MD

04:45 PM - 05:00 PM - Role of radiation therapy in the era of evolving systemic therapies - Salma Jabbour, MD 

05:00 PM - 05:15 PM - Panel Discussion

Panelists: Safae Chouraichi, PharmD, BCOP, and Simona Armanca, PharmD, BCOP

05:15 PM - 06:30 PM - RECEPTION & NETWORKING


Day 2 - September 30, 2023

07:00 AM - 08:00 AM - REGISTRATION, BREAKFAST, & NETWORKING

08:00 - 08:15 AM - Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD

08:15 AM - 08:45 AM: SPECIAL SESSION 1 - UPDATE ON NCI-SPONSORED EARLY TRIAL PROGRAM                                                       

Session Chair: Matthew Reilley, MD

Speaker: Elad Sharon, MD, MPH

08:45 AM - 09:45 AM - SESSION 2 - EVOLVING IMMUNOTHERAPY LANDSCAPE                                                                                      

Session Chair: Matthew Reilley, MD 

08:45 AM - 09:00 AM - Novel Immunotherapies: Beyond PD1/CTLA4 and LAG3 -  Ludimila Cavalcante, MD

09:00 AM - 09:15 AM - Cellular Therapies in Phase I Programs -  John Powderly, MD

09:15 AM - 09:45 AM - Panel Discussion

Panelist:  Abdul Naqash, MD

09:45 AM - 10:00 AM - BREAK & EXHIBITS

10:00 AM - 10:30 AM: KEYNOTE LECTURE - THE FDA PERSPECTIVE ON EARLY PHASE PRE-MARKET DOSE OPTIMIZATION               

Chair: John Deeken, MD

Speaker: Paul Kluetz, MD

10:30 AM - 11:00 AM: SPECIAL SESSION 2: MASTERING THE FIRST STEP: ESSENTIAL TOOLS FOR ASPIRING CLINICAL INVESTIGATORS IN PHASE I TRIALS

Moderators: Brian Van Tine, MD, PhD

Panelist: Raymond Wadlow, MD 

11:00 AM - 12:00 PM - SESSION 3: REVOLUTIONIZING CLINICAL TRIALS WITH PRECISION ONCOLOGY: A GAME CHANGER IN CANCER TREATMENT   

Session Chair: Amin Benyounes, MD 

11:00 AM - 11:15 AM - The Perfect Match: Tailoring Personalized Therapies and Clinical Trials for Optimal Patient Outcomes - Michael Pishvaian, MD, PhD

11:15 AM - 11:30 AM - “LUNGMAP study; Connecting Patients with Cutting-Edge Therapies” - Jonathan Riess, MD

11:30 AM - 11:45 AM - The Role of Liquid Biopsy in Phase I Clinical Trials - Christian Rolfo, MD, PhD, MBA

11:45 AM - 12:00 PM - Molecular Tumor Board Cases & Panel Discussion 

Panelist: Timothy Cannon, MD

12:00 PM - 12:45 PM - LUNCH & EXHIBITS

12:45 PM - 1:45 PM - SESSION 4: BREAKING BARRIERS: IMPACT OF DIVERSITY AND SPECIALIZED CARE OF RARE TUMORS

Session Chair:  Stephen Liu, MD

12:45 PM - 01:00 PM - Increasing Diversity in Clinical Trials To Reduce Health Disparities: The Time is Now -  Estelamari Rodriguez, MD, MPH

01:00 PM - 01:15 PM - Redefining Possibilities: Breaking Through the Horizons of Neuroendocrine Tumor Management - Jaydira Del Rivero, MD

01:15 PM - 01:30 PM - Cracking the KRAS Code: Novel Approaches to Targeting KRAS - Nagla Abdel Karim, MD, PhD

01:30 PM - 01:45 PM - Panel Discussion

Panelist:  Teja Poosarla, MD

01:45 PM - 02:00 PM - BREAK & EXHIBITS

02:00 PM - 03:00 PM - SESSION 5:  FUTURE OF DRUG DEVELOPMENT IN ONCOLOGY                                                                         

Session Chair: Alex Spira, MD, PhD, FACP

02:00 PM - 02:10 PM - Precision medicine and the NCI Platform Studies - Alice Chen, MD, MPH 

02:10 PM - 02:20 PM - ADC - Mohamad Salkeni, MD, FRCPC

02:20 PM - 02:30 PM - How Innovative Therapies are Breaking Barriers for Small Cell Lung Cancer - Asrar AlAhmadi, MD

02:30 PM - 03:00 PM - Panel Discussion and Q&As 

Panelist:  Triparna Sen, MS, PhD

03:00 PM - 03:30 PM: SPECIAL SESSION 3: LAYING THE FOUNDATION: "STEPS TO BUILD A SUCCESSFUL PHASE 1 PROGRAM"       

Moderator: Bassel El-Rayes, MD

Panelists: Elad Sharon, MD, MPH John Powderly, MD, and Stéphanie Gaillard, MD, PhD

03:30 PM - 03:45 PM - BREAK

03:45 PM - 04:45 PM: SESSION 6 - BEYOND THE NUMBERS: NEW PERSPECTIVES ON MEASUREMENTS OF SUCCESS                

Session Chair: Michael Winkler, MD

03:45 PM - 04:00 PM - Novel Therapies for Brain Metastases -  Manmeet Ahluwalia, MD, MBA, FASCO

04:00 PM - 04:15 PM - Artificial Intelligence in Medicine - Heejong Kim, PhD

04:15 PM - 04:30 PM - Taking RECIST Measurements into Consideration - Daniel Margolis, MD

04:30 PM - 04:45 PM - Panel Discussion 

Panelist: Tara Berman, MD

04:45 PM - 05:00 PM - Closing Remarks   

Hyatt Regency Dulles
2300 Dulles Corner Blvd
Herndon, VA 20171
United States

PLEASE NOTE THIS IS JUST FOR ATTENDEES. If you are faculty (conference chairs, session chairs, speakers, case presenters), please complete the travel form emailed to you.

A limited number of rooms have been booked at the Hyatt Regency Dulles at the discounted rates listed below:

Please follow this link to make your room reservation - 

https://www.hyatt.com/en-US/group-booking/DULLE/G-EATH

Group code: G-EATH

 

Airport Transportation

Complimentary Airport Shuttle Service is available from 24/7 to and from Dulles International Airport. If you are flying into Dulles airport, a driver will pick you up outside Ground Transportation (lower level) at curb 2B or 2G. For airport pickup between Midnight and 6:00 AM, you will need to call and request pickup. The shuttle departs every 30 minutes, based on demand, from Hyatt Regency Dulles to Dulles Airport. For departures and arrivals between 11pm and 6:30am, please sign up at the Front Desk for shuttle service.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Course Director(s)

Nagla Abdel Karim, MD, PhD

has a financial relationship (Professional Services) with Jazz, Regeneron, Amgen;.
has a financial relationship (Other) with BMS, Exelixis, Pfizer, Astra Zeneca;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Vivek Subbiah, MD

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Nagla Abdel Karim, MD, PhD

has a financial relationship (Professional Services) with Jazz, Regeneron, Amgen;.
has a financial relationship (Other) with BMS, Exelixis, Pfizer, Astra Zeneca;.

Manmeet Ahluwalia

has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with GSK;.
has a financial relationship (Independent contractor) with Pyramid Biosciences;.
has a financial relationship (Independent contractor) with SDP Oncology;.
has a financial relationship (Independent contractor) with Theraguix;.
has a financial relationship (Independent contractor) with Tocagen;.
has a financial relationship (Professional Services) with Pyramid Biosciences;.
has a financial relationship (Stock) with Cytodyn;.
has a financial relationship (Grant Or Contract) with Seagen;.
has a financial relationship (Independent contractor) with Insightec;.
has a financial relationship (Independent contractor) with Cellularity;.
has a financial relationship (Independent contractor) with Anheart Therapeutics;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Professional Services) with Cairn Therapeutics;.
has a financial relationship (Independent contractor) with Caris Lifesciences;.
has a financial relationship (Stock) with Mimivax;.
has a financial relationship (Independent contractor) with Kiyatec;.
has a financial relationship (Independent contractor) with Nuvation;.
has a financial relationship (Independent contractor) with Cairn Therapeutics;.
has a financial relationship (Independent contractor) with Prelude;.
has a financial relationship (Independent contractor) with Sumitomo Pharma Oncology;.
has a financial relationship (Independent contractor) with Viewray;.
has a financial relationship (Professional Services) with Bugworks;.
has a financial relationship (Stock) with MedInnovate Advisors LLC;.
has a financial relationship (Independent contractor) with Novocure;.
has a financial relationship (Independent contractor) with Xoft;.
has a financial relationship (Independent contractor) with Varian Medical Systems;.
has a financial relationship (Independent contractor) with Apollomics;.
has a financial relationship (Independent contractor) with Menarini Ricerche;.
has a financial relationship (Independent contractor) with Voyager Therapeutics;.
has a financial relationship (Professional Services) with Modifi biosciences;.

Asrar AlAhmadi, MBBS. MAS-CR

has a financial relationship (Professional Services) with Jazz Pharmaceutical ;.

Simona Armanca, PharmD, BCOP

has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Professional Services) with Pfizer;.

Tara Berman, MD, MS

has a financial relationship (Professional Services) with Eisai;.

Timothy Cannon, MD

has no relevant financial relationships to disclose at this time.

Ludimila Cavalcante, MD

has a financial relationship (Other) with Jansen;.
has a financial relationship (Other) with Pliant Therapeutics;.
has a financial relationship (Employment) with Actuate Therapeutics;.
has a financial relationship (Other) with CDR-Life;.

Alice Chen, MD

has no relevant financial relationships to disclose at this time.

Safae Chouraichi, PharmD, BCOP

has no relevant financial relationships to disclose at this time.

Jaydira Del Rivero, MD

has no relevant financial relationships to disclose at this time.

Stephanie Gaillard

has a financial relationship (Grant Or Contract) with Tempest;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with GenenTech/Roche;.
has a financial relationship (Professional Services) with Lumanity;.
has a financial relationship (Grant Or Contract) with NRG;.
has a financial relationship (Professional Services) with Verastem;.
has a financial relationship (Professional Services) with Curio Science;.
has a financial relationship (Grant Or Contract) with lovance;.
has a financial relationship (Financial Support) with UptoDate;.
has a financial relationship (Grant Or Contract) with Compugen;.
has a financial relationship (Professional Services) with Immunogen;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Grant Or Contract) with Tesaro/GSK;.
has a financial relationship (Grant Or Contract) with Blueprint;.
has a financial relationship (Grant Or Contract) with GOG/Clovis;.
has a financial relationship (Grant Or Contract) with NCTN;.

Salma Jabbour, M.D. Professor & Vice Chair of Clinical Research and Faculty Development

has a financial relationship (Professional Services) with Novocure;.
has a financial relationship (Professional Services) with Advarra;.
has a financial relationship (Grant Or Contract) with Beigene;.
has a financial relationship (Professional Services) with Radialogica;.
has a financial relationship (Grant Or Contract) with Merck & Co, Inc;.
has a financial relationship (Professional Services) with Merck & Co, Inc;.
has a financial relationship (Professional Services) with IMX Medical;.

Heejong Kim

has no relevant financial relationships to disclose at this time.

Paul Kluetz, Paul Kluetz, M.D.

has no relevant financial relationships to disclose at this time.

Daniel Margolis, MD

has a financial relationship (Other) with Promaxo;.

Abdul Rafeh Naqash, MD

has no relevant financial relationships to disclose at this time.

Michael Pishvaian, MD, PhD

has a financial relationship (Grant Or Contract) with Tizonia;.
has a financial relationship (Grant Or Contract) with Boerhinger Ingelheim;.
has a financial relationship (Grant Or Contract) with Actuate;.
has a financial relationship (Independent contractor) with Seattle Genetics;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Repare Tx;.
has a financial relationship (Grant Or Contract) with RenovoRx;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Independent contractor) with Ideaya;.
has a financial relationship (Independent contractor) with Novartis;.
has a financial relationship (Stock) with Perthera;.
has a financial relationship (Grant Or Contract) with Ideaya;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Hutchinson Pharma;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Trisalus;.
has a financial relationship (Grant Or Contract) with Arcus Bio;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Biomed Valley Discoveries;.
has a financial relationship (Grant Or Contract) with Asellas;.
has a financial relationship (Grant Or Contract) with Mei Pharma;.
has a financial relationship (Independent contractor) with Merus;.
has a financial relationship (Independent contractor) with RenovoRx;.
has a financial relationship (Grant Or Contract) with Tesaro;.
has a financial relationship (Grant Or Contract) with Novartis;.

Teja Poosarla

has no relevant financial relationships to disclose at this time.

John Powderly, Board Certified Oncologist; Founder and President of Carolina BioOncology Institute

has a financial relationship (Employment) with BioCytics;.
has a financial relationship (Employment) with Carolina BioOncology Institute;.

Jonathan Riess, MD, MS

has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Professional Services) with EMD Serano;.
has a financial relationship (Professional Services) with Turning Point;.
has a financial relationship (Professional Services) with Regeneron;.
has a financial relationship (Professional Services) with Biodesix;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Beigene;.

Estelamari Rodriguez, MD MPH

has a financial relationship (Other) with Daiichi;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Onc live Targeted Oncology ;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Other) with Oncohost;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Janssen;.

Christian Rolfo, MD, PhD, MBA, Dr.hc.

has a financial relationship (Financial Support) with Inivata;.
has a financial relationship (Financial Support) with Bayer;.
has a financial relationship (Other) with Imagene;.
has a financial relationship (Financial Support) with MD Serono and Novartis;.
has a financial relationship (Financial Support) with Bostongene;.
has a financial relationship (Financial Support) with Roche and MSD;.
has a financial relationship (Financial Support) with Boston Pharmaceuticals;.
has a financial relationship (Financial Support) with Regeneron;.
has a financial relationship (Other) with NCRF;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Financial Support) with Archer;.
has a financial relationship (Financial Support) with Invitae;.
has a financial relationship (Other) with LCRF- Pfizer;.

Mohamad Salkeni

has no relevant financial relationships to disclose at this time.

Triparna Sen

has no relevant financial relationships to disclose at this time.

Elad Sharon

has no relevant financial relationships to disclose at this time.

Ishwaria Subbiah, MD, MS

has no relevant financial relationships to disclose at this time.
Moderator(s)

Amin Benyounes

has no relevant financial relationships to disclose at this time.

john deeken

has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Beigene;.

Bassel El-Rayes

has no relevant financial relationships to disclose at this time.

Stephen Liu

has a financial relationship (Professional Services) with Turning Point Therapeutics;.
has a financial relationship (Grant Or Contract) with Ellipses;.
has a financial relationship (Grant Or Contract) with Merus;.
has a financial relationship (Professional Services) with Amgen;.
has a financial relationship (Other Securities) with Candel Therapeutics;.
has a financial relationship (Professional Services) with Catalyst;.
has a financial relationship (Professional Services) with Genentech/Roche;.
has a financial relationship (Professional Services) with Jazz Pharmaceuticals,;.
has a financial relationship (Professional Services) with Novartis;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Grant Or Contract) with Elevation Oncology;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Grant Or Contract) with Turning Point Therapeutics;.
has a financial relationship (Professional Services) with Bristol-Myers Squibb;.
has a financial relationship (Professional Services) with Elevation Oncology;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Mirati;.
has a financial relationship (Professional Services) with Sanofi;.
has a financial relationship (Grant Or Contract) with Alkermes;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with RAPT;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Professional Services) with Guardant Health;.
has a financial relationship (Professional Services) with Merus;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Nuvalent;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Professional Services) with Gilead;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with Regeneron;.

Matthew Reilley, MD

has a financial relationship (Professional Services) with Cardinal Health;.
has a financial relationship (Professional Services) with Cicero;.
has a financial relationship (Professional Services) with Seattle Genetics;.

Alexander Spira, MD, PhD, FACP

has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Other) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with Black Diamond Therapeutics;.
has a financial relationship (Grant Or Contract) with Boehringer Ingelheim;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Grant Or Contract) with ArriVent Biopharma;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with CytomX Therapeutics;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Grant Or Contract) with Arch Therapeutics;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Grant Or Contract) with Loxo;.
has a financial relationship (Other) with Daiichi Sankyo/Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Mirati Therapeutics;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Grant Or Contract) with mersana;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Grant Or Contract) with Medikine;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Other) with AstraZeneca/MedImmune;.
has a financial relationship (Grant Or Contract) with Scorpion Therapeutics;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Other) with Janssen Oncology;.
has a financial relationship (Grant Or Contract) with Macrogenics;.
has a financial relationship (Other) with incyte;.
has a financial relationship (Grant Or Contract) with Loxo;.
has a financial relationship (Other) with Jazz Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Other) with Gritstone Bio;.
has a financial relationship (Grant Or Contract) with Janssen Oncology;.
has a financial relationship (Other) with Black Diamond Therapeutics;.
has a financial relationship (Other) with AstraZeneca/MedImmune;.
has a financial relationship (Grant Or Contract) with Revolution Medicines;.
has a financial relationship (Grant Or Contract) with Roche;.
has a financial relationship (Other) with CytomX Therapeutics;.
has a financial relationship (Grant Or Contract) with nalo therapeutics;.
has a financial relationship (Grant Or Contract) with MedImmune;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Grant Or Contract) with Ignyta;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Grant Or Contract) with Bristol-Myers Squibb;.
has a financial relationship (Other) with Gritstone Oncology;.
has a financial relationship (Grant Or Contract) with Plexxikon;.
has a financial relationship (Other) with Mersana;.
has a financial relationship (Grant Or Contract) with ADCT;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Grant Or Contract) with Synthekine;.
has a financial relationship (Other) with Array BioPharma;.
has a financial relationship (Grant Or Contract) with Alkermes;.
has a financial relationship (Grant Or Contract) with LAM Therapeutics;.
has a financial relationship (Grant Or Contract) with BluPrint Oncology;.
has a financial relationship (Grant Or Contract) with Astellas Pharma;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Grant Or Contract) with Revolution Medicines;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Grant Or Contract) with Astex Pharmaceuticals;.
has a financial relationship (Other) with Mirati Therapeutics;.
has a financial relationship (Grant Or Contract) with Gritstone;.
has a financial relationship (Other) with Janssen Research & Development;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Other) with Regeneron;.
has a financial relationship (Grant Or Contract) with Rubius;.

Brian Van Tine, MD, PhD

has a financial relationship (Professional Services) with Kronos Bio;.
has a financial relationship (Travel) with Total Health Conference;.
has a financial relationship (Professional Services) with Boehringer Ingelheim;.
has a financial relationship (Other) with Polaris;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Advenchen;.
has a financial relationship (Professional Services) with Acuta Capital Partners, LLC;.
has a financial relationship (Professional Services) with Hinge Bio;.
has a financial relationship (Professional Services) with Total Health Conference;.
has a financial relationship (Professional Services) with PTC Therapuetics;.
has a financial relationship (Professional Services) with Curis;.
has a financial relationship (Patent) with Accuronix Therapeutics;.
has a financial relationship (Professional Services) with EcoR1;.
has a financial relationship (Professional Services) with Boxer Capital LLC;.
has a financial relationship (Professional Services) with Iterion Therapeutics, Inc.;.
has a financial relationship (Professional Services) with Apexigen,INC;.
has a financial relationship (Professional Services) with Regeneron Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Polaris;.
has a financial relationship (Professional Services) with Daiichi Sankyo Inc. ;.
has a financial relationship (Professional Services) with Salarius Pharmaceuticals, Inc.,;.
has a financial relationship (Professional Services) with Race Oncology;.
has a financial relationship (Travel) with Kronos Bio;.
has a financial relationship (Travel) with Adaptimmune;.
has a financial relationship (Professional Services) with Agenus;.
has a financial relationship (Professional Services) with Deciphera Pharmaceuticals,;.
has a financial relationship (Professional Services) with Putnam;.
has a financial relationship (Professional Services) with Aadi;.

Raymond Wadlow

has a financial relationship (Independent contractor) with Exact Sciences;.
has a financial relationship (Independent contractor) with Seagen;.
has a financial relationship (Independent contractor) with Johnson & Johnson;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Taiho;.

Michael Winkler

has a financial relationship (Independent contractor) with Teleflex;.
Committee member(s)

Alexander Spira, MD, PhD, FACP

has a financial relationship (Grant Or Contract) with Black Diamond Therapeutics;.
has a financial relationship (Grant Or Contract) with Boehringer Ingelheim;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Grant Or Contract) with ArriVent Biopharma;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Grant Or Contract) with CytomX Therapeutics;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Grant Or Contract) with Arch Therapeutics;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Grant Or Contract) with Loxo;.
has a financial relationship (Other) with Daiichi Sankyo/Astra Zeneca;.
has a financial relationship (Grant Or Contract) with Mirati Therapeutics;.
has a financial relationship (Other) with Sanofi;.
has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Other) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with Medikine;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Other) with AstraZeneca/MedImmune;.
has a financial relationship (Grant Or Contract) with Scorpion Therapeutics;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Other) with Janssen Oncology;.
has a financial relationship (Grant Or Contract) with Macrogenics;.
has a financial relationship (Other) with incyte;.
has a financial relationship (Grant Or Contract) with Loxo;.
has a financial relationship (Other) with Jazz Pharmaceuticals;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Other) with Gritstone Bio;.
has a financial relationship (Grant Or Contract) with Janssen Oncology;.
has a financial relationship (Other) with Black Diamond Therapeutics;.
has a financial relationship (Grant Or Contract) with mersana;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Grant Or Contract) with Roche;.
has a financial relationship (Other) with CytomX Therapeutics;.
has a financial relationship (Grant Or Contract) with nalo therapeutics;.
has a financial relationship (Grant Or Contract) with MedImmune;.
has a financial relationship (Other) with Amgen;.
has a financial relationship (Grant Or Contract) with Ignyta;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Grant Or Contract) with Bristol-Myers Squibb;.
has a financial relationship (Other) with Gritstone Oncology;.
has a financial relationship (Grant Or Contract) with Plexxikon;.
has a financial relationship (Other) with Mersana;.
has a financial relationship (Grant Or Contract) with ADCT;.
has a financial relationship (Other) with Lilly;.
has a financial relationship (Grant Or Contract) with Synthekine;.
has a financial relationship (Other) with AstraZeneca/MedImmune;.
has a financial relationship (Grant Or Contract) with Revolution Medicines;.
has a financial relationship (Grant Or Contract) with BluPrint Oncology;.
has a financial relationship (Grant Or Contract) with Astellas Pharma;.
has a financial relationship (Other) with Takeda;.
has a financial relationship (Grant Or Contract) with Revolution Medicines;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Other) with Bristol-Myers Squibb;.
has a financial relationship (Grant Or Contract) with Astex Pharmaceuticals;.
has a financial relationship (Other) with Mirati Therapeutics;.
has a financial relationship (Grant Or Contract) with Gritstone;.
has a financial relationship (Other) with Janssen Research & Development;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.
has a financial relationship (Other) with Regeneron;.
has a financial relationship (Grant Or Contract) with Rubius;.
has a financial relationship (Other) with Array BioPharma;.
has a financial relationship (Grant Or Contract) with Alkermes;.
has a financial relationship (Grant Or Contract) with LAM Therapeutics;.
Planning committee(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.

Commerical Support Acknowledgment:

This activity is supported with an independent medical education grant from AstraZeneca Pharmaceuticals.

 

 

 

Available Credit

  • 8.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 8.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 8.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 8.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 8.00 Contact Hours.

Price

Cost:
$100.00
Please login or register to take this course.

REGISTRATION FEES 

Physicians (non-industry) - $100

Non-physician HCP (non-industry) - $75

Industry representatives - $1250

Fellows/Residents - $0

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.